JSPR Jasper Therapeutics, Inc.
Company Analysis
Latest News
Jasper Therapeutics Completes Enrollment for Phase 2 IgA Nephropathy Clinical Trial Cohort
Jasper Therapeutics announced it has completed enrollment for the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa...
Jasper Therapeutics Announces CFO Herb Cross to Resign; Appoints Interim Leadership
Jasper Therapeutics, Inc. (JSPR) announced that Herb Cross will resign from his roles as Chief Financial Officer, Principal Financial Officer, Principal...
🔴 Jasper Therapeutics is trading 7.74% down in after-hours trading
Jasper Therapeutics is trading at $0.57, down -7.74% in after-hours trading; no clear company-specific announcement or late-breaking catalyst was identified...
🔴 Jasper Therapeutics is trading 5.3% down in pre-market
Jasper Therapeutics is trading 5.3% down at $0.60 in pre-market after reversing part of the September 17 regular-session gain. - No clear company-specific...
🔴 Jasper Therapeutics is trading 5.33% down in after-hours trading with no clear catalyst identified
Jasper Therapeutics is trading 5.33% down at $0.60 after reversing part of its September 17 regular-session gain; no clear company-specific announcement or...
🟢 Jasper Therapeutics is trading 11.9% up today as biotech stocks rally broadly
Jasper Therapeutics is trading 11.9% higher at $0.65, primarily as biotechnology stocks rally on a stronger industry outlook and M&A optimism. - XBI is up...
🟢 Jasper Therapeutics rises 6.9% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Jasper Therapeutics is trading 5.35% up today after presenting an expanded immunology strategy
Jasper Therapeutics is trading 5.35% up now at $0.60 after presenting an expanded immunology strategy at the H.C. Wainwright conference on September 16,...
Jasper Therapeutics expands immunology pipeline, backed by $140 million cash runway
Jasper Therapeutics CEO Jeet Mahal outlined an expanded immunology strategy at the H.C. Wainwright 28th Annual Global Investment Conference on September 16,...
🟢 Jasper Therapeutics is trading 5.2% up in pre-market after two senior appointments
Jasper Therapeutics is trading 5.2% up in pre-market at $0.60 after announcing two senior appointments on September 15, 2026. - Lisa Pitt was appointed Senior...
🟢 Jasper Therapeutics is trading 5.2% up in after-hours trading amid two senior regulatory and clinical appointments
Jasper Therapeutics is trading at $0.60 (+5.24%) after announcing two senior appointments covering regulatory affairs and clinical development, though their...
🟢 Jasper Therapeutics is trading 5% up in after-hours trading with no confirmed company-specific catalyst
Jasper Therapeutics is trading 5.24% up at $0.60 after closing at $0.57 on September 15, with no new company-specific catalyst identified. - No new earnings,...
🔴 Jasper Therapeutics falls 6.2% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Jasper Therapeutics is trading 7.72% down today amid broad market risk-off pressure
Jasper Therapeutics is trading 7.72% down at $0.61 after opening-market weakness on September 14, 2026, with the move most consistent with global risk-off...
🔴 Jasper Therapeutics is trading 5% down today
Jasper Therapeutics is trading 5.19% down now at $0.66, with no clear company-specific catalyst identified. - No company-specific announcement, earnings...
🔴 Jasper Therapeutics is trading 7.56% down today in pre-market with no clear company-specific catalyst identified
Jasper Therapeutics is trading 7.56% down at $0.66 after no clear company-specific announcement was identified for September 8, 2026. - The latest readily...
Jasper Therapeutics Proposes Reverse Split, Aiming to Save Nasdaq Listing
Jasper Therapeutics, Inc. scheduled a special stockholder meeting for September 30, 2026. Shareholders will vote on a proposed reverse stock split at a ratio...
🔴 Jasper Therapeutics is trading 5.16% down in pre-market as catalyst remains unclear
Jasper Therapeutics is trading at $0.65 (-5.16%) before the September 4, 2026 open, with no clear company-specific catalyst identified. - The...
🔴 Jasper Therapeutics is trading 6.23% down today as the catalyst remains unclear
Jasper Therapeutics is trading at $0.66, down 6.23%, as no clear company-specific announcement has emerged on September 3, 2026. - The company’s...
🔴 Jasper Therapeutics is trading 12.33% down today in pre-market as U.S.-Iran tensions pressured biotech shares
Jasper Therapeutics is trading 12.33% down now at $0.61 after U.S.-Iran tensions lifted oil prices and pressured biotechnology shares. - It fell 5.29% in...